118 related articles for article (PubMed ID: 38050147)
21. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract][Full Text] [Related]
23. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
[TBL] [Abstract][Full Text] [Related]
24. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
25. Prostate Specific Membrane Antigen Targeted
Gorin MA; Rowe SP; Patel HD; Vidal I; Mana-Ay M; Javadi MS; Solnes LB; Ross AE; Schaeffer EM; Bivalacqua TJ; Partin AW; Pienta KJ; Szabo Z; De Marzo AM; Pomper MG; Allaf ME
J Urol; 2018 Jan; 199(1):126-132. PubMed ID: 28736318
[TBL] [Abstract][Full Text] [Related]
26. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
27. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of thresholding methods for the quantification of [
Kim M; Seifert R; Fragemann J; Kersting D; Murray J; Jonske F; Pomykala KL; Egger J; Fendler WP; Herrmann K; Kleesiek J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2196-2209. PubMed ID: 36859618
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
30. Pathological predictors of
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Sutherland TR
BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
[TBL] [Abstract][Full Text] [Related]
31. Head-to-Head Comparison of
Sonni I; Felker ER; Lenis AT; Sisk AE; Bahri S; Allen-Auerbach M; Armstrong WR; Suvannarerg V; Tubtawee T; Grogan T; Elashoff D; Eiber M; Raman SS; Czernin J; Reiter RE; Calais J
J Nucl Med; 2022 Jun; 63(6):847-854. PubMed ID: 34649942
[TBL] [Abstract][Full Text] [Related]
32. Optimal
Draulans C; De Roover R; van der Heide UA; Kerkmeijer L; Smeenk RJ; Pos F; Vogel WV; Nagarajah J; Janssen M; Isebaert S; Maes F; Mai C; Oyen R; Joniau S; Kunze-Busch M; Goffin K; Haustermans K
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1211-1218. PubMed ID: 33025093
[TBL] [Abstract][Full Text] [Related]
33. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with
Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP
Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693
[TBL] [Abstract][Full Text] [Related]
34. Prospective Evaluation of PSMA-Targeted
Rowe SP; Campbell SP; Mana-Ay M; Szabo Z; Allaf ME; Pienta KJ; Pomper MG; Ross AE; Gorin MA
J Nucl Med; 2020 Jan; 61(1):58-61. PubMed ID: 31201249
[TBL] [Abstract][Full Text] [Related]
35. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
36. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
37. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
[TBL] [Abstract][Full Text] [Related]
38. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
39. Higher Preoperative Maximum Standardised Uptake Values (SUV
de Bie KCC; Veerman H; Bodar YJL; Meijer D; van Leeuwen PJ; van der Poel HG; Donswijk ML; Vis AN; Oprea-Lager DE
Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510087
[TBL] [Abstract][Full Text] [Related]
40. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
